Celsion (CLSN) Closes $15M Private Placement
Tweet
Share
E-mailGet Alerts CLSN Hot Sheet
Join SI Premium – FREE
Celsion Corporation (Nasdaq: CLSN) has closed its previously announced sale of $15 million of the Company's securities to leading life science institutional investors in a private placement offering.
The Company received approximately $13.9 million in net proceeds from the offering, after deducting placement agent fees and estimated offering expenses. The Company intends to use the net proceeds from the offering for general corporate purposes, including the funding of the clinical development of its Phase III HEAT Study, a multinational, double-blind, placebo-controlled, pivotal study of ThermoDox in combination with radio frequency ablation (RFA) for hepatocellular carcinoma (HCC) or primary liver cancer.
The Company received approximately $13.9 million in net proceeds from the offering, after deducting placement agent fees and estimated offering expenses. The Company intends to use the net proceeds from the offering for general corporate purposes, including the funding of the clinical development of its Phase III HEAT Study, a multinational, double-blind, placebo-controlled, pivotal study of ThermoDox in combination with radio frequency ablation (RFA) for hepatocellular carcinoma (HCC) or primary liver cancer.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BKV registers 5.3 million shares for resale tied to power JV deal
- Zeo Energy Corp (ZEO) files $150M mixed shelf
- PMI and Altria strike cigarette contract manufacturing deal
Create E-mail Alert Related Categories
Corporate News, Equity OfferingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
